New Zealand Data Sheet

1. PRODUCT NAME

DermAid® Cream

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

DermAid 0.5% Cream (0.5% w/w hydrocortisone)
DermAid 1.0% Cream (1.0% w/w hydrocortisone)

Excipient(s) with known effect

DermAid Cream contains cetostearyl alcohol, cetyl alcohol and benzyl alcohol.
For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Non-greasy white topical cream.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

DermAid Cream is indicated for topical application for the temporary relief of symptoms associated with acute and chronic corticosteroid-responsive conditions including, minor skin irritations, itching and rashes due to eczema, dermatitis, contact dermatitis (such as rashes due to cosmetics and jewellery), psoriasis, anogenital pruritus and sunburn.

4.2. Dose and method of administration

For external use only.

DermAid 0.5% Cream: A thin layer should be applied to the affected skin one to three times a day as required.

DermAid 1% Cream: A thin layer should be applied to the affected skin one to two times a day as required. Once the inflammation has subsided the frequency of use may be reduced.

In atopic dermatitis (eczema), a rebound of pre-existing dermatoses can occur with abrupt discontinuation of topical corticosteroid preparations. Therapy with topical corticosteroids should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy.
4.3. Contraindications

Like all other topical corticosteroids, DermAid Cream is contraindicated in vaccinia, chicken pox, herpes and other viral infections, bacterial infections, tuberculosis of the skin and syphilitic skin disorders.

Do not use in the eye.

Hypersensitivity to hydrocortisone, other corticosteroids or any other ingredient in the product.

4.4. Special warnings and precautions for use

Long-term continuous topical therapy should be avoided where possible, particularly in children, as adrenal suppression can occur (even without occlusion).

As with other topical corticosteroids, when extensive areas are treated, sufficient systemic absorption may occur to produce the features of hypercorticalism. This effect is more likely to result if occlusive dressings are used or if treatment is prolonged. Rarely, local atrophy or striae may occur after prolonged treatment. This must be borne in mind when treating conditions such as severe eczema and seborrhoeic dermatitis. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye as glaucoma may result. Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions that have become infected.

Any spread of the infection requires withdrawal of corticosteroid therapy and systemic administration of antimicrobial agents. Bacterial infection is encouraged by the warm, moist conditions associated by occlusive dressings, so the skin should be cleansed prior to a fresh dressing being applied.

Patients in whom there is a risk of increased systemic absorption should be regularly evaluated for evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression by using urinary free cortisol (hydrocortisone) tests and monitoring morning plasma cortisol levels.

If there is evidence of suppression, attempts should be made to withdraw the drug or reduce the frequency of application. If hypersensitivity occurs, stop application and institute appropriate therapy. If irritation occurs, discontinue use. Systemic absorption of topical corticosteroids will be increased if extensive body surface areas are treated or if occlusion is used. Suitable precautions should be taken under these conditions or when long-term use is anticipated.

Hydrocortisone may mask signs of infection. If any infection is present, an appropriate anti-infective agent should be used first. DermAid Cream may be used to reduce inflammation but if a favourable response does not occur promptly then use of the product should be discontinued until the infection has been adequately controlled.
Use of the product near the eyes should be avoided. If any skin irritation develops discontinue use and treat appropriately. If extensive areas are treated, or if occlusive dressings are used, the possibility also exists of increased systemic absorption and this in turn could lead to the depression of the hypothalamo-pituitary-adrenal axis. In all such patients it is essential to monitor adrenal function at regular intervals.

**Visual disturbance**

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.

**Paediatric population**

The risk of systemic absorption, and hence systemic toxicity, is greater in children due to a larger skin surface to body weight ratio than adults. The preparation is not recommended for use in children under 2 years of age except on the advice of a doctor.

4.5. Interaction with other medicines and other forms of interaction

No interactions known.

4.6. Fertility, pregnancy and lactation

**Fertility**

No data available.

**Pregnancy**

Category A: Drugs which have been taken by a large number of pregnant women and women of child bearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed.

**Breast-feeding**

It is not known whether sufficient absorption of topical corticosteroids takes place to be excreted in breast milk. The potential benefits should be weighed against possible hazards to the breastfeeding infant.

4.7. Effects on ability to drive and use machines

None known.

4.8. Undesirable effects

**General disorders and administration site conditions**
“Rebound effect”, see section 4.2.

After the application of DermAid Cream a slight stinging sensation may occasionally be noticed. This transient symptom is most likely to disappear after several applications.

**Skin and Subcutaneous Tissue Disorders**

The following adverse effects have been reported with topical steroids: burning; itching; irritation; skin atrophy; secondary infection; dryness; acneform eruptions and hypo-pigmentation. Treatment should be chiefly symptomatic and administration of the steroid should be discontinued.

Intolerance to the occlusive dressing (Miliary eruptions, folliculitis) may be expected to be observed, as with other corticosteroids. In such cases the use of an occlusive dressing should be discontinued. Use of the steroid may also need to be reduced or discontinued as local atrophy and striae of the skin may be observed.

**Other**

In long-term treatment of extensive skin areas with occlusive dressings, one should bear in mind the possibility of inhibition of adrenal function. Therefore, adrenal function should be monitored under these circumstances.

Systemic adverse reactions, such as blurred vision, have also been reported with the use of topical corticosteroids, see Section 4.4.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)

**4.9. Overdose**

Percutaneous absorption of corticosteroids may occur, especially under occlusive conditions. The following adverse effects have been reported with topical steroids: burning; itching; irritation; skin atrophy; secondary infection; dryness; acneform eruptions and hypo-pigmentation. Treatment should be chiefly symptomatic and administration of the steroid should be discontinued.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

**5. PHARMACOLOGICAL PROPERTIES**

**5.1. Pharmacodynamic properties**

Pharmacotherapeutic group: Corticosteroids, weak (group I); ATC code: D07A A02
DermAid Cream contains dissolved hydrocortisone. Creams with dissolved hydrocortisone have been shown to be pharmacologically more active than creams with suspended hydrocortisone in causing vasoconstriction. The active component, hydrocortisone, has anti-inflammatory, anti-eczematous, anti-allergic and anti-pruritic properties.

5.2. Pharmacokinetic properties

Metabolism

Hydrocortisone is metabolised in the liver most likely by reduction of the 5,6 double bond and the C3 and C20 keto groups. The resultant hydroxy derivatives are then conjugated with glucuronic acid. Cortisone, an 11-keto-steroid is formed from hydrocortisone; the 11-keto-steroids are then reduced and conjugated to yield glucuronide metabolites. A small percentage of hydrocortisone is converted to the 17-keto-steroid. The C21 hydroxyl group is conjugated with sulphate.

Excretion

When radioactive-carbon, ring-labelled steroids are injected intravenously in man, most of the radioisotope is recovered in the urine within 72 hours. Neither biliary nor faecal excretion is of any quantitative importance in man. It has been estimated that the liver metabolises at least 70% of the hydrocortisone secreted.

5.3. Preclinical safety data

No specific data available.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients

DermAid Cream contains: water, cetomacrogol 1000, cetostearyl alcohol, cetyl alcohol, self-emulsifying glyceryl monostearate, macrogol 400, propylene glycol and benzyl alcohol (as preservative).

6.2. Incompatibilities

None known.

6.3. Shelf life

36 months.

6.4. Special precautions for storage

Store at or below 25°C. Do not refrigerate.

6.5. Nature and contents of container
Tube, plastic, 15g and 30g.

Not all strengths or pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Any unused medicinal products or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE

DermAid 0.5% Cream: Pharmacy Only Medicine
DermAid 1.0% Cream: Pharmacist Only Medicine

8. SPONSOR

Douglas Pharmaceuticals Ltd
P O Box 45 027
Auckland 0651
New Zealand
Phone: (09) 835 0660

9. DATE OF FIRST APPROVAL

DermAid 0.5% Cream: 11 October 1989
DermAid 1.0% Cream: 13 September 2001

10. DATE OF REVISION OF THE TEXT

24 February 2022

Summary table of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>Addition of a rebound note as per Medsafe request. Added “For external use only”.</td>
</tr>
<tr>
<td>4.3</td>
<td>Addition of “bacterial infections” as per reference product information.</td>
</tr>
<tr>
<td>4.4</td>
<td>Addition of “for external use only” statement</td>
</tr>
<tr>
<td>4.5</td>
<td>Section reworded “None known” to “No interactions known”.</td>
</tr>
<tr>
<td>4.8</td>
<td>Reference to blurred vision as per section 4.4 added.</td>
</tr>
<tr>
<td>5.2</td>
<td>Added headings “metabolism” and “excretion” to text.</td>
</tr>
</tbody>
</table>